share_log

NAYA Biosciences Announces Development Of NY-500 Novel AI-Optimized PD-1 X VEGF Bifunctional Antibody

NAYA Biosciences Announces Development Of NY-500 Novel AI-Optimized PD-1 X VEGF Bifunctional Antibody

NAYA生物科學公司宣佈開發NY-500新型人工智能優化的PD-1與VEGF雙功能抗體
Benzinga ·  01/06 21:32

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications

PD-1 x VEGF抗體顯示出有潛力超越免疫檢查點抑制劑成爲多種腫瘤適應症的標準治療。

• NAYA aiming to initiate clinical trials in early 2026

• NAYA計劃於2026年初啓動臨牀試驗

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論